Avalyn Pharma Inc. (AVLN)

Avalyn Pharma Inc. Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	Dec 31, 2025	Dec 31, 2024
Cash & Equivalents	52.32	23.96
Short-Term Investments	86.04	86.67
Cash & Cash Equivalents	138.36	110.63
Cash Growth	25.07%	-
Other Current Assets	5.2	3.76
Total Current Assets	143.56	114.39
Property, Plant & Equipment	0.79	0.09
Long-Term Investments	-	7.49
Goodwill and Intangibles	1.53	-
Other Long-Term Assets	3	2.55
Total Long-Term Assets	5.32	10.13
Total Assets	148.88	124.52
Accounts Payable	3.76	2.28
Current Debt	0.44	-
Other Current Liabilities	9.89	6.47
Total Current Liabilities	14.09	8.74
Long-Term Debt	1.23	-
Total Long-Term Liabilities	1.23	0
Total Liabilities	15.32	8.74
Total Debt	1.67	0
Retained Earnings	-265.36	-180.16
Comprehensive Income	0.13	0.2
Shareholders' Equity	-238.66	-174.52
Net Cash (Debt)	136.69	110.63
Net Cash (Debt) Growth	23.56%	-
Working Capital	129.47	105.64

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).